[go: up one dir, main page]

MX2018000684A - Composiciones y metodos antitusivos. - Google Patents

Composiciones y metodos antitusivos.

Info

Publication number
MX2018000684A
MX2018000684A MX2018000684A MX2018000684A MX2018000684A MX 2018000684 A MX2018000684 A MX 2018000684A MX 2018000684 A MX2018000684 A MX 2018000684A MX 2018000684 A MX2018000684 A MX 2018000684A MX 2018000684 A MX2018000684 A MX 2018000684A
Authority
MX
Mexico
Prior art keywords
methods
compositions
antitussive compositions
antitussive
treating
Prior art date
Application number
MX2018000684A
Other languages
English (en)
Inventor
Liang Jing
DICPINIGAITIS Peter
Canning Brendan
Devita Robert
Original Assignee
Attenua Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Attenua Inc filed Critical Attenua Inc
Publication of MX2018000684A publication Critical patent/MX2018000684A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/465—Nicotine; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/14—Antitussive agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

En la presente se describen composiciones que incluyen agonistas del receptor nicotí­nico, especí­ficamente de los subtipos nAChR a4íŸ2 o a7, y métodos para tratar o suprimir la tos.
MX2018000684A 2015-07-31 2016-07-28 Composiciones y metodos antitusivos. MX2018000684A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562199353P 2015-07-31 2015-07-31
US15/208,266 US9724340B2 (en) 2015-07-31 2016-07-12 Antitussive compositions and methods
PCT/US2016/044529 WO2017023700A1 (en) 2015-07-31 2016-07-28 Antitussive compositions and methods

Publications (1)

Publication Number Publication Date
MX2018000684A true MX2018000684A (es) 2018-07-06

Family

ID=57886252

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018000684A MX2018000684A (es) 2015-07-31 2016-07-28 Composiciones y metodos antitusivos.

Country Status (15)

Country Link
US (2) US9724340B2 (es)
EP (1) EP3328383A4 (es)
JP (1) JP2018522020A (es)
KR (1) KR20180033201A (es)
CN (1) CN107847493A (es)
AU (1) AU2016302769A1 (es)
BR (1) BR112018001938A2 (es)
CA (1) CA2994150A1 (es)
HK (1) HK1250015A1 (es)
IL (1) IL257167A (es)
MX (1) MX2018000684A (es)
PH (1) PH12018500118A1 (es)
TW (1) TW201717945A (es)
WO (1) WO2017023700A1 (es)
ZA (1) ZA201800213B (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018152554A1 (en) * 2017-05-22 2018-08-23 Attenua, Inc. Antitussive compositions and methods
CN110507618A (zh) * 2019-09-05 2019-11-29 杭州百诚医药科技股份有限公司 一种乙酰半胱氨酸颗粒剂及其制备方法
JP7682627B2 (ja) * 2019-12-24 2025-05-26 アリナミン製薬株式会社 医薬組成物
WO2021222230A1 (en) * 2020-04-28 2021-11-04 Oyster Point Pharma, Inc. Local administration of nicotinic acetylcholine receptor agonists for the inhibition of coronavirus infections

Family Cites Families (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4203990A (en) 1979-04-30 1980-05-20 G. D. Searle & Co. Anti-diarrheal 2-substituted quinuclidines
EP0353189B1 (de) 1988-07-28 1994-01-12 Ciba-Geigy Ag Kupfer- und Nickeldihalogenidkomplexe, Verfahren zu deren Herstellung und deren Verwendung
US4922901A (en) 1988-09-08 1990-05-08 R. J. Reynolds Tobacco Company Drug delivery articles utilizing electrical energy
EP0402056A3 (en) 1989-06-06 1991-09-04 Beecham Group p.l.c. Azabicyclic compounds, process for their preparation and pharmaceutical compositions containing them
EP0412798A3 (en) 1989-08-08 1992-07-01 Merck Sharp & Dohme Ltd. Substituted pyridines, their preparation, formulations and use in dementia
IN173570B (es) 1989-11-23 1994-06-04 Pfizer
DK40890D0 (da) 1990-02-16 1990-02-16 Ferrosan As Substituerede urinstofforbindelser, deres fremstilling og anvendelse
EP0492903A1 (en) 1990-12-21 1992-07-01 MERCK SHARP & DOHME LTD. Substituted pyrazines, pyrimidines and pyridazines for use in the treatment of glaucoma
US5212188A (en) 1992-03-02 1993-05-18 R. J. Reynolds Tabacco Company Method for treatment of neurodegenerative diseases
US5276043A (en) 1992-04-10 1994-01-04 R. J. Reynolds Tobacco Company Method for treatment of neurodegenerative diseases
IL107184A (en) 1992-10-09 1997-08-14 Abbott Lab Heterocyclic ether compounds that enhance cognitive function
US5852041A (en) 1993-04-07 1998-12-22 Sibia Neurosciences, Inc. Substituted pyridines useful as modulators of acethylcholine receptors
AU7474794A (en) 1993-07-22 1995-02-20 E.I. Du Pont De Nemours And Company Arthropodicidal azacyclic heterocycles
US5493026A (en) 1993-10-25 1996-02-20 Organix, Inc. Substituted 2-carboxyalkyl-3-(fluorophenyl)-8-(3-halopropen-2-yl) nortropanes and their use as imaging for agents for neurodegenerative disorders
US5510355A (en) 1994-09-06 1996-04-23 Bencherif; Merouane Depolarizing skeletal muscle relaxants
US5998404A (en) 1994-10-24 1999-12-07 Eli Lilly And Company Heterocyclic compounds and their use
US5616707A (en) 1995-01-06 1997-04-01 Crooks; Peter A. Compounds which are useful for prevention and treatment of central nervous system disorders
US5604231A (en) 1995-01-06 1997-02-18 Smith; Carr J. Pharmaceutical compositions for prevention and treatment of ulcerative colitis
US5824692A (en) 1995-01-06 1998-10-20 Lippiello; Patrick Michael Pharmaceutical compositions for prevention and treatment of central nervous system disorders
US5597919A (en) 1995-01-06 1997-01-28 Dull; Gary M. Pyrimidinyl or Pyridinyl alkenyl amine compounds
WO1996025160A1 (en) 1995-02-17 1996-08-22 Novo Nordisk A/S The use of heterocyclic compounds
US5585388A (en) 1995-04-07 1996-12-17 Sibia Neurosciences, Inc. Substituted pyridines useful as modulators of acetylcholine receptors
US5583140A (en) 1995-05-17 1996-12-10 Bencherif; Merouane Pharmaceutical compositions for the treatment of central nervous system disorders
IL118279A (en) 1995-06-07 2006-10-05 Abbott Lab Compounds 3 - Pyridyloxy (or Thio) Alkyl Heterocyclic Pharmaceutical Compositions Containing Them and Their Uses for Preparing Drugs to Control Synaptic Chemical Transmission
JPH08337532A (ja) * 1995-06-14 1996-12-24 Takeda Chem Ind Ltd 医薬組成物
JPH11508540A (ja) 1995-06-29 1999-07-27 ノボ ノルディスク アクティーゼルスカブ 新規の置換アザ環式またはアザ二環式化合物
EP0853621A1 (en) 1995-09-22 1998-07-22 Novo Nordisk A/S Novel substituted azacyclic or azabicyclic compounds
US5712270A (en) 1995-11-06 1998-01-27 American Home Products Corporation 2-arylamidothiazole derivatives with CNS activity
US5616716A (en) 1996-01-06 1997-04-01 Dull; Gary M. (3-(5-ethoxypyridin)yl)-alkenyl 1 amine compounds
SE9600683D0 (sv) 1996-02-23 1996-02-23 Astra Ab Azabicyclic esters of carbamic acids useful in therapy
US5663356A (en) 1996-04-23 1997-09-02 Ruecroft; Graham Method for preparation of aryl substituted alefinic secondary amino compounds
US5726189A (en) 1996-05-03 1998-03-10 The United States Of America, Represented By The Secretary, Department Of Health And Human Services Method for imaging nicotinic acetylcholinergic receptors in the brain using radiolabeled pyridyl-7-azabicyclo 2.2.1!heptanes
ZA9711092B (en) 1996-12-11 1999-07-22 Smithkline Beecham Corp Novel compounds.
US5861423A (en) 1997-02-21 1999-01-19 Caldwell; William Scott Pharmaceutical compositions incorporating aryl substituted olefinic amine compounds
US5811442A (en) 1997-02-21 1998-09-22 Bencherif; Merouane Pharmaceutical compositions for the treatment of conditions associated with decreased blood flow
ATE267199T1 (de) 1997-05-30 2004-06-15 Neurosearch As 8-azabicyclo(3,2,1)oct-2-en- und octanderivate als liganden der nicotinergen ach rezeptoren
AR013184A1 (es) 1997-07-18 2000-12-13 Astrazeneca Ab Aminas heterociclicas espiroazobiciclicas, composicion farmaceutica, uso de dichas aminas para preparar medicamentos y metodo de tratamiento o profilaxis
US5952339A (en) 1998-04-02 1999-09-14 Bencherif; Merouane Pharmaceutical compositions and methods of using nicotinic antagonists for treating a condition or disorder characterized by alteration in normal neurotransmitter release
DK1068208T3 (da) 1998-04-02 2003-09-01 Targacept Inc Azatricyclo[3.3.1.1]dekanderivater og farmaceutiske sammensætninger, der indeholder dem
ATE255888T1 (de) 1998-06-01 2003-12-15 Ortho Mcneil Pharm Inc Tetrahydronaphtalene verbindungen und deren verwendung zur behandlung von neurodegenerativen krankheiten
US6432975B1 (en) 1998-12-11 2002-08-13 Targacept, Inc. Pharmaceutical compositions and methods for use
US6953855B2 (en) 1998-12-11 2005-10-11 Targacept, Inc. 3-substituted-2(arylalkyl)-1-azabicycloalkanes and methods of use thereof
US6734215B2 (en) 1998-12-16 2004-05-11 University Of South Florida Exo-S-mecamylamine formulation and use in treatment
JP2001064167A (ja) * 1999-08-27 2001-03-13 Kyorin Pharmaceut Co Ltd 医薬組成物
SE9904176D0 (sv) 1999-11-18 1999-11-18 Astra Ab New use
GB0010955D0 (en) 2000-05-05 2000-06-28 Novartis Ag Organic compounds
DK1300407T4 (da) 2000-06-27 2011-09-05 S A L V A T Lab Sa Carbamater afledt af arylalkylaminer
WO2002016356A2 (en) 2000-08-18 2002-02-28 Pharmacia & Upjohn Company Quinuclidine-substituted aryl moieties for treatment of disease (nicotinic acetylcholine receptor ligands)
JP2004506735A (ja) 2000-08-18 2004-03-04 ファルマシア・アンド・アップジョン・カンパニー 疾患治療用キヌクリジン置換アリール化合物
US6486172B2 (en) 2000-08-18 2002-11-26 Pharmacia & Upjohn Company Quinuclidine-substituted aryl compounds for treatment of disease
US6599916B2 (en) 2000-08-21 2003-07-29 Pharmacia & Upjohn Company Quinuclidine-substituted heteroaryl moieties for treatment of disease
WO2002017358A2 (en) 2000-08-21 2002-02-28 Pharmacia & Upjohn Company Quinuclidine-substituted heteroaryl moieties for treatment of disease (nicotinic acetylcholine receptor antagonists)
HUP0303529A3 (en) 2000-12-22 2008-03-28 Almirall Ag New quinuclidine carbamate derivatives, process for their preparation and pharmaceutical compositions containing them and their use
AR037211A1 (es) * 2001-11-07 2004-10-27 Schering Corp Derivados de heteroarilo como ligandos superiores para el receptor de nociceptina orl-1
AU2003208967A1 (en) * 2002-02-04 2003-09-02 Pharmacia Corporation A combination for treating cold and cough
US7820663B2 (en) * 2005-06-17 2010-10-26 The Regents Of The University Of California Substituted enaminones, their derivatives and uses thereof
US20080003280A1 (en) 2006-06-26 2008-01-03 Levine Brian M Combination cough treatment compounds and method of treating common coughs
AU2007281224A1 (en) * 2006-07-29 2008-02-07 Graceway Pharmaceuticals, Llc Methods and pharmaceutical compositions to treat gastric acid disorders
SA08290475B1 (ar) 2007-08-02 2013-06-22 Targacept Inc (2s، 3r)-n-(2-((3-بيردينيل)ميثيل)-1-آزا بيسيكلو[2، 2، 2]أوكت-3-يل)بنزو فيوران-2-كربوكساميد، وصور أملاحه الجديدة وطرق استخدامه
TW201031664A (en) 2009-01-26 2010-09-01 Targacept Inc Preparation and therapeutic applications of (2S,3R)-N-2-((3-pyridinyl)methyl)-1-azabicyclo[2.2.2]oct-3-yl)-3,5-difluorobenzamide
EP2706854A4 (en) * 2011-05-09 2014-12-03 Envivo Pharmaceuticals Inc TREATMENT OF COGNITIVE DISORDERS BY CERTAIN AGONISTS OF THE ALPHA-7 NICOTINIC RECEPTOR IN COMBINATION WITH NICOTINE
CN102219786A (zh) * 2011-06-07 2011-10-19 南京泽朗农业发展有限公司 一种金雀花碱的制备方法

Also Published As

Publication number Publication date
CN107847493A (zh) 2018-03-27
CA2994150A1 (en) 2017-02-09
TW201717945A (zh) 2017-06-01
US9724340B2 (en) 2017-08-08
AU2016302769A1 (en) 2018-02-01
EP3328383A1 (en) 2018-06-06
US20170027918A1 (en) 2017-02-02
EP3328383A4 (en) 2019-01-16
WO2017023700A1 (en) 2017-02-09
KR20180033201A (ko) 2018-04-02
PH12018500118A1 (en) 2018-07-23
JP2018522020A (ja) 2018-08-09
BR112018001938A2 (pt) 2018-09-18
HK1250015A1 (zh) 2018-11-23
IL257167A (en) 2018-03-29
US20170273957A1 (en) 2017-09-28
ZA201800213B (en) 2018-12-19

Similar Documents

Publication Publication Date Title
MX2019003623A (es) Composiciones y metodos para el tratamiento de afecciones oftalmicas.
PH12018500907A1 (en) Inhibitors of ret
MX2021000710A (es) Composiciones que comprenden cepas bacterianas.
TW201613966A (en) SynTac polypeptides and uses thereof
PH12016502142B1 (en) Anti-ptk7 antibody-drug conjugates
MX2020005213A (es) Inhibidores de proteina cinasa 2 activada por proteina cinasa activada por mitogeno (mk2) y sus usos.
PH12017500660A1 (en) Novel compositions, uses and methods for making them
MX391052B (es) Represores de htt y usos de estos.
MY192927A (en) Fused bicyclic compounds for the treatment of disease
GB2541571A (en) Pharmaceutical compositions
MX2017008456A (es) Compuestos biciclicos fusionados para el tratamiento de enfermedades.
MX2018000715A (es) Metodos para tratar cancer usando apilimod.
MX2019005833A (es) Administracion transdermica de agentes grandes.
PH12017501028A1 (en) Treatment of retinal degeneration using progenitor cells
EP3609528A4 (en) COMPOSITIONS FOR THE TREATMENT OF ADDICTION
DK3658142T3 (en) Compositions and methods for treating galactosemia
PH12017501022B1 (en) Compositions comprising 15-hepe and methods of treating or preventing fibrosis using same
MX2017010883A (es) Composicion para el tratamiento de la infertilidad.
HK1255835A1 (zh) 用於治疗乙型肝炎的治疗组合物及方法
PH12017500602A1 (en) Methods for treating ocular conditions
MX2017011116A (es) Composiciones novedosas, usos y metodos para hacerlas.
WO2018094106A3 (en) ALLOSTERIC ANTAGONISTS OF GPRC6a AND THEIR USE IN MITIGATING PROTEINOPATHIES
PH12018500118A1 (en) Antitussive compositions and methods
MX382092B (es) Compuestos heterocíclicos para el tratamiento de enfermedades.
MX2015009153A (es) Uso de agonistas del receptor nicotinico de acetilcolina alfa 7.